To evaluate this hypothesis, a mouse model of non-small cell lung cancer (NSCLC) with subcutaneous transplant tumors was established, and the anti-tumor effects of the combined therapy using anti-CD47 Ab and anti-CTLA4 Ab were assessed. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.